Tag: Silence Therapeutics

Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development

Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&D, following his retirement by year-end LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing […]

Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer

LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the appointment of J.P. Gabriel as Chief Technical Operations Officer […]

Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting

– Assessment showed participants who received a single dose of SLN360 maintained median reductions over 80% over a five-month period November 05, 2022 10:30 AM Eastern Daylight Time LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and […]

Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting

– SLN360 reduced Lp(a) – a key genetic risk factor for heart disease – by up to 98% with reductions of up to 81% persisting at 150 days – Results were simultaneously published in The Journal of the American Medical Association (JAMA) […]